Adeno-associated viral (AAV) vectors are one of the most promising gene delivery systems to the central nervous system. We now report, that AAV1 can be used to express transgenes trans-neuronally in neurons distant from the injection site. Specifically, intracortical injection of a bicistronic AAV1 vector trans-neuronally transduced spinal neurons as shown by fluorescence microscopy, the presence of AAV genome and AAV transcript in the contralateral spinal cord. Prior pyramidotomy abolished spinal transduction, confirming anterograde axonal transport of AAV1 in the corticospinal tract. These observations demonstrate the potential of bicistronic AAV1 for trans-neuronal expression of therapeutic transgenes in neurological disorders or reporter genes in connectivity studies.
INTRODUCTION
One of the most complex challenges facing systems neuroscience is the mapping of neuronal pathways in the intact and injured mammalian central nervous system (CNS). Furthermore, increasing the distribution of therapeutic genes within the injured or diseased CNS and developing the ability to assess neuronal plasticity after a therapeutic intervention are key goals in regenerative medicine.
Existing methods for anterograde, trans-neuronal delivery of therapeutic transgenes or tract-tracing include the use of live herpes simplex virus or dual viral vector-mediated WGA-Cre systems, 1, 2 which are complex and challenging to employ. By comparison, recombinant-deficient adeno-associated viral (AAV) vectors are a leading, simple, safe gene delivery system for the CNS that can undergo anterograde axonal transport in vivo. [3] [4] [5] [6] [7] [8] [9] [10] [11] Pseudotyping an AAV genome with the capsid from a different AAV serotype can generate vectors with different cellular tropisms as well as different axonal transport properties, which can improve the efficiency and pattern of transduction to specific regions of the CNS. [11] [12] [13] [14] Evidence for trans-neuronal transduction exists, but has been confounded by the possibility of vector diffusion and the presence of reciprocal axonal connections between injection site and distal sites of transduction.
Anterograde axonal transport of AAV1, 2 and 5 has been previously demonstrated by detecting AAV vector genome in the spinal cord following injection into the brain. 4, 7 However the presence and cellular location of the protein product expressed by the AAV vector was either not investigated 7 or not found to be increased. 4 Using AAV vector serotypes 1, 2, 6 and 9, several independent studies have observed transduced neurons in brain regions distal to the AAV injection site, suggesting that these vectors can undergo anterograde axonal transport to projection sites where the AAV vectors are released to transduce local neurons. However, the close proximity of the projection sites to the injection site and the existence of multiple reciprocal connections between brain regions limit what definitive conclusions can be drawn. 5, 6, [9] [10] [11] Other studies report the presence of a growth factor protein in neurons at sites distal to an AAV injection; however, this may be due to axonal transport, secretion and re-uptake of the growth factor protein rather than transport of the AAV vector. 8, 15, 16 We previously reported AAV1 as the optimal serotype for transducing corticospinal neurons following cortical injection. 17, 18 The corticospinal tract (CST) is a major descending sensorimotor tract originating from the corticospinal neurons in layer V of the cortex (Figure 1a) . 19 The CST axons project through the medullary pyramids in the ventral brainstem, where the majority of fibres decussate to the contralateral side. In the rat, the bulk of corticospinal axons run in the dorsal medial spinal cord, with minor components running in the dorso-lateral and the ventral medial columns. 20 CST axon collaterals arborise predominantly in intermediate spinal laminae, however, terminations are also found in dorsal and ventral laminae (Figure 1a) . 21, 22 Here, we demonstrate trans-neuronal transduction of second-order contralateral spinal neurons following cortical injection and anterograde axonal transport of a bicistronic AAV1 vector in the corticospinal tract.
RESULTS
Intracortical delivery of AAV1-mCherry-2A-eGFP resulted in anterograde axonal transport and trans-neuronal transduction of spinal neurons in the contralateral spinal cord, which was abolished by prior pyramidotomy Six weeks after unilateral injection of the bicistronic AAV1-mCherry-2A-eGFP vector into the right sensorimotor cortex, we observed extensive transduction of the injected cortex including the corticospinal neurons in layer V as well as neurons in layers 2/3 ( Figure 1b ). mCherry and enhanced green fluorescent protein (eGFP)-positive fibre bundles projecting to the pyramids were observed in the striatum, the internal capsule and cerebral peduncles (Figure 1b) . Transgene-positive transcallosal fibres were observed projecting to the contralateral cortex (Figure 1b 24 and substantia nigra (Figure 1f) . 25 In the spinal cord we observed numerous mCherry and eGFPpositive CST axons in the dorsal columns of the left (contralateral) spinal cord, although collaterals in grey matter were not intensely stained ( Figure 1c ). We also observed many transduced NeuNpositive spinal neurons expressing both mCherry and eGFP in the contralateral grey matter, with occasional transduced spinal neurons also in the right (ipsilateral) grey matter ( Figure 1c ). These results are consistent with the trajectory of the rat CST whose major component decussates at the medullary pyramids and runs in the contralateral spinal cord, with a minor component of uncrossed axons running in the ipsilateral spinal cord (Figure 1a) . 21, 26 Importantly, when the CST was unilaterally lesioned by performing a pyramidotomy 27 1 week before ipsilateral cortical AAV1 injection, the transduced axons and spinal neurons were no longer observed in the spinal cord.
Intracortical injection of AAV1-mCherry-2A-eGFP resulted in increased levels of the vector genome DNA and mRNA transcript in the contralateral spinal cord, which was abolished by prior pyramidotomy Following AAV1 injection into the right cortex, the amount of AAV genome (mCherry DNA) or transcript (mCherry mRNA) was analysed in each cortical hemisphere using quantitative PCR and qRT-PCR (quantitative PCR after reverse transcription). Significantly higher levels of mCherry DNA (n = 6/group, two-way analysis of variance (ANOVA), brain hemisphere P o 0.0001, Figures 2a and b) and mCherry mRNA (n = 6/group, two-way ANOVA, brain hemisphere P o0.0001, Figures 3a and b) were detected in the injected cortical hemisphere, compared with the uninjected cortical hemisphere. There was no difference in the amount of mCherry DNA or mRNA detected in each hemisphere between the uninjured and pyramidotomised animals (n = 6/group two-way ANOVA group P40.05, Figures 2a and b, 3a and b). Low levels of AAV genome and transcript were detected in the uninjected cortex that is likely due to axonal transport of vector particles between cortical hemispheres: mCherry and GFP-positive callosal fibres and transduced cortical neurons in the contralateral cortex were observed to support this (Figures 1a and c) .
Analysis of each half of the cervical spinal cords confirmed that mCherry DNA (n = 6/group, two-way ANOVA, post hoc Fisher's least significant difference (LSD) Po0.0001, Figures 2a and c) and mRNA (n = 6/group, two-way ANOVA, post hoc Fisher's LSD Po0.02, Figures 2a and c) was significantly increased in the contralateral spinal cord compared with the ipsilateral. Low levels of mCherry DNA and mRNA was also detected on the ipsilateral side, which is consistent with the decussation pattern of the CST axons. When the CST was unilaterally lesioned 1 week before AAV1 injection, significantly lower levels of mCherry DNA (n = 6/group two-way ANOVA, group Po0.001, Figures 2a and c) and mRNA (n = 6/group two-way ANOVA, group P = 0.01 Figures 3a and c) were detected in the spinal cord compared with the uninjured animals.
DISCUSSION
In this study, we demonstrate the trans-neuronal transduction of spinal neurons in the contralateral spinal cord following cortical injection and anterograde axonal transport of a bicistronic AAV1 vector. Specifically, we observed the expression of mCherry and eGFP reporter proteins in second-order spinal neurons and the detection of AAV vector genome and transcript in the contralateral spinal cord following intracortical AAV1 injection, which were both abolished by prior pyramidotomy.
Two previous studies have detected AAV1 genome in the spinal cord following brain injections. 4, 7 Following injection of an AAV1 vector encoding vascular endothelial growth factor (VEGF) into the motor cortex and internal capsule, Bucher et al. detected VGEF RNA and protein throughout the injected hemisphere of the feline brain. Anterograde transport of the AAV1 vectors into the spinal cord was confirmed by the presence of VEGF DNA and mRNA throughout the spinal cord. However, despite this, no increase in VEGF protein level was detected in the spinal cord. 4 The authors suggest that the vector genome may be confined to spinal axons where it is unable to be translated; this apparent lack of distal trans-neuronal transduction and protein expression in the spinal cord is at odds with our findings. This may be due to differences in AAV titre, injection location or volume; although we can't rule out that it could be due to a property of our bicistronic AAV1 vector that is not shared with other AAV1 vectors. In a separate study by Ciron et al., AAV1 vector genome was detected throughout the spinal cord following injection into the putamen and internal capsule of the non-human primate brain. Within the spinal cord, higher levels of the AAV vector genome were primarily detected in the contralateral spinal cord, which is consistent with our findings. However the level of expression or cellular location of the AAV protein product (human α-iduronidase) was not investigated. 7 Others have reported the presence of a transgene protein product at sites distant from an AAV injection within the brain, but in these studies the vectors expressed growth factor proteins and transport, secretion and re-uptake of the protein itself cannot be ruled out. 8, 15, 16 We observed neuronal transduction in brain regions that receive direct connections from the site of AAV injection. These observations are consistent with previous studies that have reported anterograde axonal transport of various AAV serotypes and trans-neuronal transduction within the brain.
5,6,9-11 However, due to the presence of multiple reciprocal connections between brain regions, retrograde axonal transport of the AAV vector cannot be completely excluded, and neither can vector diffusion from the injection site. In contrast, we also provide evidence of spinal neuron transduction in a pattern consistent with the termination of the corticospinal axons and that was abolished following a prior pyramidotomy, confirming that this bicistronic AAV1 may only trans-neuronally transduce neurons that express α2,3 and α2,6N-linked sialic acids on their cell surface, 28 highlighting the importance of identifying the optimal AAV vector serotype for the transduction of the target neuronal population. Prior overexpression of these sialic acids or development of new capsids should enable AAVs to be used for trans-neuronal transduction of additional pathways and neuronal populations.
In conclusion, we report that this bicistronic AAV1 vector provides a novel method of investigating spinal circuitries, for assessing plasticity and increasing the distribution of transgenes within the CNS. Diseases that affect specific neuronal circuits such as Motor neuron disease, Parkinson's disease, stroke and spinal cord injury may benefit from trans-neuronal transfer of therapeutic transgenes. 
MATERIALS AND METHODS
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plasmid was generated by amplifying mCherry and eGFP using PCR, followed by ligation into the psubCMV-2A-WPRE plasmid, 18 for detailed methods on the cloning procedure. The bicistronic AAV1-mCherry-2A-eGFP vector was made as a control for another experiment, where mCherry was replaced by a gene of interest. While analysing tissue from that experiment we noticed what appeared to be trans-neuronal transduction and decided to investigate this serendipitous observation further.
AAV vector production
The bicistronic AAV1-mCherry-2A-eGFP vector uses a Foot and Mouth Virus 2A sequence to express two separate fluorescent proteins from a single promoter by causing ribosomal skipping during protein translation. AAV1-mCherry-2A-eGFP vector was generated by the Miami Project Viral Vector Core using fast protein liquid chromatography-based purification and pseudotyped with AAV capsid serotype 1; the vector titre was 2.9 × 10 13 GC per ml. A separate batch of AAV1-mCherry-2A-eGFP vector was also produced by UPenn viral vector core for independent verification; the vector titre was 1.3 × 10 13 GC per ml. Similar results were obtained with both vectors.
Animals
Experiments were performed on 24 adult female Lister hooded rats weighing between 200 and 250 g (Harlan, Blackthorn, UK). All procedures were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and approved by the local veterinarian and ethical committee.
Intracortical injections
Rats were anaesthetised with an intraperitoneal injection of 0.5 mg kg − 1 Domitor (medetomidine hydrochloride) and 100 mg kg − 1 Vetelar (ketamine hydrochloride) and body temperature was maintained at 37°C. This procedure has been previously described in detail. 18 Briefly, the head was placed into a stereotaxic frame (World Precision Instruments, Sarasota, FL, USA) and seven holes were drilled with a micro-drill (Power Performance, Longford, UK) using coordinates reported in a microstimulation study 29 relative to Bregma, defined as anteriorposterior (AP), medial-lateral (ML): 1st +3.5 mm ML, − 0.5 mm AP; 2nd +3.5 mm ML, +0.5 mm AP; 3rd +3.5 mm ML, +2 mm AP; 4th +2.5 mm ML, +1.5 mm AP; 5th +2.5 mm ML, +0.5 mm AP; 6th +1.5 mm ML, +1 mm AP; 7th +2 mm ML, +3.5 mm AP. A total of 3.5 μl (0.5 μl per hole) of the AAV1 vector was injected at a depth of 1.5 mm into the cortex, at a rate of 150 nl min − 1 . The skin was then sutured, 1 mg kg − 1 Antisedan (atipamezole hydrochloride) was administered subcutaneously and the rats were placed in an incubator at 37°C. Once awake, 5 mg kg − 1 Carprofen was administered for postoperative analgesia.
Pyramidotomy surgery
To determine whether trans-neuronal transport occurred in the corticospinal tract, six rats received pyramidotomy 1 week before intracortical injection of AAV. Using our routine methods for pyramidotomy, 27 rats were anaesthetised with 2% isoflurane in O 2 and their body temperature was maintained at 37°C. A midline incision was made along the throat, the trachea was displaced to one side and the muscle was blunt dissected to expose the basioccipital skull. A craniotomy of the occipital bone was performed to allow for access to the medullary pyramids. The right pyramid was cut using Vannas microscissors medially up to the basilar artery. The wound was closed with 3-0 sutures and the rats were placed in an incubator at 32°C. Once fully awake, 5 mg kg
Carprofen was administered for postoperative analgesia.
Histology Six weeks post-AAV injection, 12 rats (six uninjured and six pyramidotomised) were terminally anaesthetised by intraperitoneal injection of 400 mg kg − 1 sodium pentobarbital and transcardially perfused with phosphate-buffered saline (PBS; pH 7.4) followed by 4% paraformaldehyde in PBS. Brains and spinal cords were dissected, post fixed in 4% paraformaldehyde for 4 h and cryoprotected in 30% sucrose (Sigma, Gillingham, UK). Brains were embedded in 10% porcine gelatin (Sigma), cut rostro-caudally into 50 μm free floating coronal sections using a vibratome (Leica, Peterborough, UK), mounted and coverslipped with Mowiol. Cervical spinal cords were embedded in OCT and frozen with liquid nitrogen. Spinal cords were cut transversely into 30 μm sections using a cryostat and mounted immediately on glass slides.
Immunohistochemistry and imaging
Spinal cord sections were washed with 0.3% Triton-X-100 in PBS (PBST) and stained with primary antibody against NeuN (mouse monoclonal, 1:500, Abcam, Cambridge, UK) diluted in PBST with 10% normal goat serum for 24 h at room temperature. The sections were then washed with PBS and incubated with secondary antibody (1:1000, goat anti-mouse DyLight 650, Invitrogen, Paisley, UK) diluted in PBST for 2 h at room temperature. Sections were then washed with PBS and coverslipped with Mowiol. Mosaic images were captured using a Zeiss Apotome fluorescent microscope (Carl Zeiss, Welwyn Garden City, UK).
Tissue preparation for PCR analysis Six weeks post-AAV injection, 12 rats (six uninjured and six pyramidotomised) were terminally anaethetised with sodium pentobarbital and transcardially perfused with PBS. The cerebral cortex around the injection site and the cervical spinal cord were dissected and the left and right hemispheres or sides were separated by cutting sagittally along the midline. The tissue was then snap frozen in liquid nitrogen and stored at − 80 1C.
DNA and mRNA extraction Genomic DNA was extracted using a DNeasy kit (Qiagen, Manchester, UK) that included RNase treatment (Qiagen). For RNA extraction tissue samples were homogenised in Trizol (Invitrogen) and total RNA extracted using a combination of a phenol-chloroform extraction and an RNeasy kit (Qiagen) that included DNase treatment (Qiagen). For cDNA synthesis 400 ng RNA was reverse transcribed using the Superscript II kit (Invitrogen) according to manufacturer's protocol. qPCR qPCR was performed using the Roche LightCycler 480 II and SYBR Green master mix (Roche, Welwyn Garden City, UK). Samples underwent an initial denaturation at 95 1C for 10 mins. Samples were amplified for 40 cycles (60 1C for 10 s, 72 1C for 20 s, 95 1C for 10 s) and then a final extension at 72 1C for 1 min. Forward and reverse primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and mCherry were designed using NCBI Primer-Blast software (Bethesda, MD, USA). Primer sequences were: GAPDH forward 5′-ATG-GGA-AGC-TGG-TCA-TCA-AC-3′ and reverse 5′-CCA-CAG-TCT-TCT-GAG-TGG-CA-3′. mCherry forward 5′-GCG-CCT-ACA-ACG-TCA-ACA-TC-3′ and reverse 5′-GCG-TTC-GTA-CTG-TTC-CAC-GA-3′. Transcript levels were measured and normalised against GAPDH. Two technical repeats were performed per animal. A no-template negative control was included and gel electrophoresis of the PCR products along with melt-curve analysis confirmed primer specificity, PCR products of the expected size, and the absence of primer dimer.
Statistical analysis Data was analysed with the appropriate parametric test using Prism 6 (GraphPad, La Jolla, CA, USA). PCR data were analysed with two-way ANOVA followed by Fisher's LSD test. Results are expressed as mean ± s.e.m.
